CA2124553A1 - Pharmaceutical Tablet Capable of Releasing the Active Ingredients Contained Therein at Subsequent Times - Google Patents

Pharmaceutical Tablet Capable of Releasing the Active Ingredients Contained Therein at Subsequent Times

Info

Publication number
CA2124553A1
CA2124553A1 CA2124553A CA2124553A CA2124553A1 CA 2124553 A1 CA2124553 A1 CA 2124553A1 CA 2124553 A CA2124553 A CA 2124553A CA 2124553 A CA2124553 A CA 2124553A CA 2124553 A1 CA2124553 A1 CA 2124553A1
Authority
CA
Canada
Prior art keywords
releasing
active ingredients
ingredients contained
subsequent times
pharmaceutical tablet
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2124553A
Other languages
French (fr)
Other versions
CA2124553C (en
Inventor
Ubaldo Conte
Aldo La Manna
Lauretta Maggi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jagotec AG
Original Assignee
Ekita Investments NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ekita Investments NV filed Critical Ekita Investments NV
Publication of CA2124553A1 publication Critical patent/CA2124553A1/en
Application granted granted Critical
Publication of CA2124553C publication Critical patent/CA2124553C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms

Abstract

A pharmaceutical tablet capable of releasing the active ingredients contained therein at subsequent times produced via the steps of: a) preparing a tablet consisting of three superposed layers, the upper layer containing an active ingredient, the intermediate layer not containing any active ingredient and forming a barrier-type layer, and the lower layer containing an active ingredient, said upper layer presenting a raised top, b) coating the tablet entirely with an impermeable polymeric film, and c) removing said raised top and thus allowing contact of the abraded upper layer surface with the environment.
CA002124553A 1993-05-31 1994-05-27 Pharmaceutical tablet capable of releasing the active ingredients contained therein at subsequent times Expired - Lifetime CA2124553C (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT93MI001120A IT1264517B1 (en) 1993-05-31 1993-05-31 PHARMACEUTICAL TABLET SUITABLE FOR THE RELEASE IN SUBSEQUENT TIMES OF THE ACTIVE PRINCIPLES CARRIED THEREIN
ITMI93A001120 1993-05-31

Publications (2)

Publication Number Publication Date
CA2124553A1 true CA2124553A1 (en) 1994-12-01
CA2124553C CA2124553C (en) 2000-04-18

Family

ID=11366293

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002124553A Expired - Lifetime CA2124553C (en) 1993-05-31 1994-05-27 Pharmaceutical tablet capable of releasing the active ingredients contained therein at subsequent times

Country Status (13)

Country Link
US (2) US5487901A (en)
EP (1) EP0631775B1 (en)
JP (1) JPH07138150A (en)
AT (1) ATE183386T1 (en)
AU (1) AU677833B2 (en)
CA (1) CA2124553C (en)
DE (1) DE69420087T2 (en)
DK (1) DK0631775T3 (en)
ES (1) ES2138633T3 (en)
GR (1) GR3031841T3 (en)
IT (1) IT1264517B1 (en)
NZ (1) NZ260630A (en)
SI (1) SI0631775T1 (en)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI93924C (en) * 1991-09-17 1995-06-26 Martti Lauri Antero Marvola A method of preparing a controlled release formulation
US6183778B1 (en) 1993-09-21 2001-02-06 Jagotec Ag Pharmaceutical tablet capable of liberating one or more drugs at different release rates
GB9407386D0 (en) 1994-04-14 1994-06-08 Smithkline Beecham Plc Pharmaceutical formulation
US5534263A (en) * 1995-02-24 1996-07-09 Alza Corporation Active agent dosage form comprising a matrix and at least two insoluble bands
EP0812195B1 (en) * 1995-02-28 2002-10-30 Aventis Pharmaceuticals Inc. Pharmaceutical composition for piperidinoalkanol compounds
US20030109503A1 (en) * 1995-06-06 2003-06-12 Smithkline Beecham P.L.C. Pharmaceutical formulations comprising clavulanic acid alone or in combination with other beta-lactam antibiotics
IT1282576B1 (en) * 1996-02-06 1998-03-31 Jagotec Ag PHARMACEUTICAL TABLET SUITABLE TO GIVE THE ACTIVE SUBSTANCE IN SUBSEQUENT AND PREDETERMINABLE TIMES
IT1282650B1 (en) * 1996-02-19 1998-03-31 Jagotec Ag PHARMACEUTICAL TABLET, CHARACTERIZED BY A HIGH INCREASE IN VOLUME IN CONTACT WITH BIOLOGICAL LIQUIDS
AU4219497A (en) * 1996-09-13 1998-04-02 Shionogi & Co., Ltd. Sustained-release preparation utilizing thermal change and process for the production thereof
US20030124187A1 (en) * 1997-02-14 2003-07-03 Smithkline Beecham Laboratoires Pharmaceutiques, Pharmaceutical formulations comprising amoxycillin and clavulanate
PT998272E (en) * 1997-08-26 2003-09-30 Aventis Pharma Inc PHARMACEUTICAL COMPOSITION FOR COMBINATION OF PIPERIDINOALCANOL DECONGESTIONANT
IN186245B (en) 1997-09-19 2001-07-14 Ranbaxy Lab Ltd
US5843477A (en) * 1997-09-30 1998-12-01 Bayer Corporation Lubricants for use in tabletting
US6465009B1 (en) 1998-03-18 2002-10-15 Yamanouchi Pharmaceutical Co., Ltd. Water soluble polymer-based rapidly dissolving tablets and production processes thereof
US20030153607A1 (en) * 1998-11-12 2003-08-14 Smithkline Beecham P.L.C. Novel composition and use
US20090060995A1 (en) * 2005-01-13 2009-03-05 Kamalinder Kaur Singh Dispersible sustained release pharmaceutical compositions
US6878386B1 (en) 1999-04-13 2005-04-12 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection comprising amoxycillin and potassium clavulanate
US6294199B1 (en) 1999-04-13 2001-09-25 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection comprising administering amoxycillin
US7250176B1 (en) * 1999-04-13 2007-07-31 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection
EP1064937A1 (en) * 1999-06-28 2001-01-03 Sanofi-Synthelabo Timed dual release dosage forms comprising a short acting hypnotic or a salt thereof
US6555139B2 (en) 1999-06-28 2003-04-29 Wockhardt Europe Limited Preparation of micron-size pharmaceutical particles by microfluidization
US6245913B1 (en) 1999-06-30 2001-06-12 Wockhardt Europe Limited Synthetic procedure for 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methylthio]-IH-benzimidazole hydrochloride and its conversion to omeprazole
AU2276801A (en) 1999-12-20 2001-07-03 Schering Corporation Extended release oral dosage composition
AU2277101A (en) * 1999-12-20 2001-07-03 Schering Corporation Stable extended release oral dosage composition
AR030557A1 (en) * 2000-04-14 2003-08-27 Jagotec Ag A TABLET IN MULTI-MAP OF CONTROLLED RELEASE AND TREATMENT METHOD
US6372252B1 (en) 2000-04-28 2002-04-16 Adams Laboratories, Inc. Guaifenesin sustained release formulation and tablets
US7985420B2 (en) * 2000-04-28 2011-07-26 Reckitt Benckiser Inc. Sustained release of guaifenesin combination drugs
US8012504B2 (en) * 2000-04-28 2011-09-06 Reckitt Benckiser Inc. Sustained release of guaifenesin combination drugs
US7838032B2 (en) * 2000-04-28 2010-11-23 Reckitt Benckiser Inc. Sustained release of guaifenesin
US6955821B2 (en) 2000-04-28 2005-10-18 Adams Laboratories, Inc. Sustained release formulations of guaifenesin and additional drug ingredients
US6756057B2 (en) 2000-10-12 2004-06-29 Beecham Pharmaceuticals (Pte) Limited Amoxicillin and potassium clavulanate dosage form
EP1330236A2 (en) 2000-10-12 2003-07-30 Beecham Pharmaceuticals (Pte) Limited Formulation containing amoxicillin
EP1245227A1 (en) 2001-03-31 2002-10-02 Jagotec Ag A pharmaceutical tablet system that floats in the stomach for programmed release of active substance and process of producing buoyant material contained in same
US20030070584A1 (en) 2001-05-15 2003-04-17 Cynthia Gulian Dip coating compositions containing cellulose ethers
US20040156903A1 (en) * 2002-05-22 2004-08-12 Abrams Andrew L.. Metering and packaging of controlled release medication
US7052706B2 (en) * 2001-06-08 2006-05-30 Nostrum Pharmaceuticals, Inc. Control release formulation containing a hydrophobic material as the sustained release agent
EP1295926A1 (en) 2001-09-19 2003-03-26 ExxonMobil Chemical Patents Inc. Components for adhesive compositions and process for manufacture
US8309118B2 (en) 2001-09-28 2012-11-13 Mcneil-Ppc, Inc. Film forming compositions containing sucralose
US20030104052A1 (en) * 2001-10-25 2003-06-05 Bret Berner Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
US20030091630A1 (en) * 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
CA2409552A1 (en) * 2001-10-25 2003-04-25 Depomed, Inc. Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
US20030152622A1 (en) * 2001-10-25 2003-08-14 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral diuretic
GB0203296D0 (en) 2002-02-12 2002-03-27 Glaxo Group Ltd Novel composition
ITMI20020515A1 (en) * 2002-03-12 2003-09-12 Jagotec Ag SYSTEM FOR THE CONTROLLED RELEASE OF ONE OR MORE ACTIVE INGREDIENTS
ITMI20020514A1 (en) * 2002-03-12 2003-09-12 Jagotec Ag THERAPEUTIC SYSTEM FOR THE CONTROLLED RELEASE OF ONE OR MORE ACTIVE PRINCIPLES
US20060013875A1 (en) * 2002-05-29 2006-01-19 Impax Laboratories, Inc. Combination immediate release controlled release levodopa/carbidopa dosage forms
US8637512B2 (en) 2002-07-29 2014-01-28 Glaxo Group Limited Formulations and method of treatment
US7429619B2 (en) 2002-08-02 2008-09-30 Mcneil Consumer Healthcare Polyacrylic film forming compositions
US20040115265A1 (en) * 2002-12-11 2004-06-17 Loutfy Benkerrour Multilayered tablet containing pravastatin and aspirin and method
PE20050335A1 (en) * 2003-08-07 2005-06-01 Sb Pharmco Inc ORAL DOSAGE FORM INCLUDING 5- [4- [2- (N-METHYL-N- (2-PYRIDYL) AMINO) ETOXY] BENZYL] THIAZOLIDIN-2,4-DIONA AND PROCEDURE FOR THE PREPARATION
EP1663175B1 (en) * 2003-09-19 2012-03-28 Sun Pharma Advanced Research Company Limited Oral drug delivery system
US10213387B2 (en) 2003-09-19 2019-02-26 Sun Pharma Advanced Research Company Ltd. Oral drug delivery system
US10226428B2 (en) 2003-09-19 2019-03-12 Sun Pharma Advanced Research Company Ltd. Oral drug delivery system
US7595335B2 (en) * 2003-10-28 2009-09-29 Pierre Fabre Medicament Pharmaceutical composition based on idazoxan, salts, hydrates or polymorphs thereof
FR2861299B1 (en) 2003-10-28 2006-01-27 Pf Medicament PHARMACEUTICAL COMPOSITIONS BASED ON IDASOXAN DERIVATIVES IN POLYMORPHIC FORMS
US8476307B2 (en) * 2003-10-28 2013-07-02 Pierre Fabre Medicament Pharmaceutical composition based on idazoxan, salts, hydrates or polymorphs thereof
US20050202079A1 (en) * 2004-03-15 2005-09-15 Mylan Pharmaceuticals Inc. Novel orally administrable formulation of nitrofurantoin and a method for preparing said formulation
US7318935B2 (en) * 2004-05-21 2008-01-15 Accu-Break Technologies, Inc. Pharmaceutical tablets with active and inactive segments
JP4681843B2 (en) * 2004-09-30 2011-05-11 日本臓器製薬株式会社 Solid pharmaceutical formulation
US20090264495A1 (en) * 2005-02-17 2009-10-22 Standard Chem. & Pharm. Co., Ltd. Oral sustained-release pharmaceutical composition of indapamide, production and use thereof
US20060182803A1 (en) * 2005-02-17 2006-08-17 Standard Chem. & Pharm. Co., Ltd. Oral sustained-release pharmaceutical composition of indapamide, production and use thereof
US20060243809A1 (en) * 2005-04-27 2006-11-02 Hodgson Rodney T Combination logo and identification code
WO2007058660A1 (en) * 2005-11-18 2007-05-24 Accu-Break Technologies, Inc. Segmented pharmaceutical dosage forms
US20090087483A1 (en) * 2007-09-27 2009-04-02 Sison Raymundo A Oral dosage combination pharmaceutical packaging
US8439033B2 (en) 2007-10-09 2013-05-14 Microdose Therapeutx, Inc. Inhalation device
EP2242485A4 (en) * 2008-02-15 2013-05-08 Sun Pharma Advanced Res Co Ltd Oral controlled release tablet
US20100233259A1 (en) * 2008-12-12 2010-09-16 Pascal Grenier Dosage form of ropinirole
US10485770B2 (en) 2009-12-21 2019-11-26 Aptapharma, Inc. Functionally-coated multilayer tablets
WO2011085022A1 (en) * 2010-01-05 2011-07-14 Microdose Therapeutx, Inc. Inhalation device and method
BR112012030708A2 (en) * 2010-06-01 2016-11-01 Grünenthal S A ibuprofen pharmaceutical compositions and an h2 receptor antagonist
AU2012277375A1 (en) * 2011-06-29 2014-01-30 Sun Pharmaceutical Industries Limited Multilayered dosage form
GB201303781D0 (en) 2013-03-04 2013-04-17 Gauthier Pierre Pascal Oral timer device and method of using same
US10987313B2 (en) 2013-10-07 2021-04-27 Impax Laboratories, Llc Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
EP3782614A1 (en) 2013-10-07 2021-02-24 Impax Laboratories, LLC Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
CA2987114A1 (en) 2015-06-03 2016-12-08 Triastek, Inc. Method of 3d printing oral dosage forms having a drug in a compartment sealed by an erodibleplug
US11278506B2 (en) 2015-10-09 2022-03-22 Rb Health (Us) Llc Pharmaceutical formulation
RU2602681C1 (en) * 2015-11-09 2016-11-20 Федеральное государственное бюджетное образовательное учреждение высшего образования Первый Московский государственный медицинский университет имени И.М. Сеченова Министерства здравоохранения Российской Федерации (ФГБОУ ВО Первый МГМУ им. И.М. Сеченова Минздрава России) Method of producing diclofenac capsules
MX2019006742A (en) 2016-12-09 2019-09-05 Bayer Animal Health Gmbh Pharmaceutical preparation and method for its manufacture.
WO2018137686A1 (en) * 2017-01-26 2018-08-02 Triastek, Inc. Dosage forms of controlled release at specific gastrointestinal sites
USD907235S1 (en) * 2017-09-18 2021-01-05 University Of Hertfordshire Higher Education Corporation Enclosure for dissolution system
US11571391B2 (en) 2018-01-09 2023-02-07 Triastek, Inc. Oral drug dosage forms compromising a fixed-dose of an ADHD non-stimulant and an ADHD stimulant
WO2020255837A1 (en) * 2019-06-17 2020-12-24 東和薬品株式会社 Timed-elution masking particles and oral pharmaceutical composition containing same
CN115624125B (en) * 2022-10-28 2024-03-08 广州王老吉大健康产业有限公司 Effervescent tablet and preparation method thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2100858B1 (en) * 1970-07-03 1975-06-06 Daiichi Seiyaku Co
EP0230654B1 (en) * 1985-12-28 1992-03-18 Sumitomo Pharmaceuticals Company, Limited Sustained pulsewise release pharmaceutical preparation
IT1201136B (en) * 1987-01-13 1989-01-27 Resa Farma TABLET FOR PHARMACEUTICAL USE SUITABLE FOR THE RELEASE OF SUBSTANCES OF ACTIVE SUBSTANCES

Also Published As

Publication number Publication date
AU6342694A (en) 1994-12-08
CA2124553C (en) 2000-04-18
DE69420087D1 (en) 1999-09-23
AU677833B2 (en) 1997-05-08
ITMI931120A0 (en) 1993-05-31
IT1264517B1 (en) 1996-09-24
EP0631775B1 (en) 1999-08-18
JPH07138150A (en) 1995-05-30
ITMI931120A1 (en) 1994-12-01
SI0631775T1 (en) 2000-02-29
ATE183386T1 (en) 1999-09-15
ES2138633T3 (en) 2000-01-16
EP0631775A1 (en) 1995-01-04
GR3031841T3 (en) 2000-02-29
DE69420087T2 (en) 2000-03-23
US5650169A (en) 1997-07-22
US5487901A (en) 1996-01-30
DK0631775T3 (en) 2000-03-06
NZ260630A (en) 1995-08-28

Similar Documents

Publication Publication Date Title
CA2124553A1 (en) Pharmaceutical Tablet Capable of Releasing the Active Ingredients Contained Therein at Subsequent Times
CA2196840A1 (en) Pharmaceutical tablet suitable to deliver the active substance in subsequent and predeterminable times
CA2145513A1 (en) Pharmaceutical Tablet Capable of Liberating One or More Drugs at Different Release Rates
CA2304110A1 (en) Theophylline sustained release tablet
CA2044398A1 (en) Programmed release oral solid pharmaceutical dosage form
CA2316277A1 (en) Tablet for instant and prolonged release of one or more active substances
HU9303504D0 (en) Process for producing retard composition with diffusive-osmotic release
NZ336462A (en) Pharmaceutical composition of fenofibrate with high biological availability
CA2239778A1 (en) Apparatus for controlling the registration of two continuously moving layers of material and an article made thereby
CA2354472A1 (en) Conversion of liquid filled gelatin capsules into controlled release systems by multiple coatings
JPS649930A (en) Device for drug control release
NO912470D0 (en) PROCEDURE FOR THE PREPARATION OF A COMPOSITE LAYER ON A SUBSTRATE IN A DEVICE CONTAINING ELECTROLYTE IN STANDARD CONDITION.
CA2170647A1 (en) Multiple unit tableted dosage form i
CA2391406A1 (en) Multi-layer preparation in film form, consisting of hydrophilic polymers, for the rapid release of active ingredients
CA2310585A1 (en) Novel administration form comprising an acid-labile active compound
EP0235718A3 (en) Granule remaining in stomach
CA2179103A1 (en) Multi-layer golf ball
FR2711528B1 (en) Use of Saccharomyces yeasts for the manufacture of a medicament against cryptosporidiosis.
WO1999014078A3 (en) Non-blocking filter
CA2005049A1 (en) Method of fabricating cylindrical ceramic laminated body
USD340480S (en) Indoor boomerang
USD372749S (en) Amusement ball
USD359077S (en) Game board
USD274222S (en) Bottle
USD318418S (en) Pharmaceutical tablet dispenser

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20140527